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Abstract
Background: The product of CDKN2A, p16 is an essential regulator of the cell cycle controlling the entry into the S-
phase. Herein, we evaluated CDKN2A promoter methylation and p16 protein expression for the differentiation of 
hepatocellular carcinoma (HCC) from other liver tumors.
Methods: Tumor and corresponding non-tumor liver tissue samples were obtained from 85 patients with liver tumors. 
CDKN2A promoter methylation was studied using MethyLight technique and methylation-specific PCR (MSP). In the 
MethyLight analysis, samples with ≥ 4% of PMR (percentage of methylated reference) were regarded as 
hypermethylated. p16 expression was evaluated by immunohistochemistry in tissue sections (n = 148) obtained from 
81 patients using an immunoreactivity score (IRS) ranging from 0 (no expression) to 6 (strong expression).
Results: Hypermethylation of the CDKN2A promoter was found in 23 HCCs (69.7%; mean PMR = 42.34 ± 27.8%), six 
(20.7%; mean PMR = 31.85 ± 18%) liver metastases and in the extralesional tissue of only one patient. Using MSP, 32% of 
the non-tumor (n = 85), 70% of the HCCs, 40% of the CCCs and 24% of the liver metastases were hypermethylated. 
Correspondingly, nuclear p16 expression was found immunohistochemically in five (10.9%, mean IRS = 0.5) HCCs, 23 
(92%; mean IRS = 4.9) metastases and only occasionally in hepatocytes of non-lesional liver tissues (mean IRS = 1.2). The 
difference of CDKN2A-methylation and p16 protein expression between HCCs and liver metastases was statistically 
significant (p < 0.01, respectively).
Conclusion: Promoter methylation of CDKN2A gene and lack of p16 expression characterize patients with HCC.
Background
Hepatocellular carcinoma (HCC) shows a dramatic
increase of its incidence worldwide over the last three
decades [1] and is associated with a very poor prognosis
[2,3]. Except for patients accessible for surgical therapy,
the 5-year survival is less than 3% [2,3]. Chronic hepatitis
B virus (HBV) with or without additional exposure to
aflatoxin [4,5], chronic hepatitis C virus (HCV), and alco-
hol are the main risk factors of HCC [2,3,6]. Diagnosis is
usually made at an advanced stage of the disease, and
poorly differentiated tumors are sometimes a challenge
for liver-pathologists.
Many types of cancers have an abnormal control of the
transition from G1 to S phase of the cell cycle. CDKN2A
is regarded as tumour suppressor gene because it is fre-
quently silenced by deletion or inactivating mutation in
human cancers [7-9]. The product of CDKN2A, p16 is a
potent cyclin-dependent kinase inhibitor and a critical
negative G1-specific regulator that halts cell-cycle pro-
gression at the G1-S-phase boundary. Loss of its function
can lead to uncontrolled cell proliferation [7].
Hui et al. were the first to report that p16 is commonly
deleted in HCC [10]. Initially, it was believed that inacti-
vation of p16 in patients with primary liver cancer is
related to homozygous deletions and mutations of
CDKN2A gene [11-13]. Evidence is, however, increasing
that gene silencing can also be achieved by methylation of
CpG islands of the promoter region [14]. CDKN2A gene
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was reported to be extensively methylated in patients
with HCC [15]. Indeed, methylation of CDKN2A was
found not only in HCC, but also in patients with chronic
liver disease [16,17] indicating that this finding may be
non-specific for liver cancer. However, previous investi-
gations used methylation-specific PCR (MSP) [18], a
technique with limited sensitivity and specificity [19,20].
In our study, we investigated promoter methylation of
CDKN2A using a novel sensitive method, MethyLight
assay, in addition to the standard method of MSP, and p16
expression to identify and differentiate HCC from non-
HCC liver tumors in a series of patients presenting with a
liver mass.
Methods
Patients and tissue samples
Tumor and corresponding non-neoplastic liver tissue
specimens were obtained from 85 patients who under-
went surgical resection. Tissue samples were stored at -
80°C until analysis.
Hepatocellular carcinoma (HCC)
Patients with HCC consisted of 28 men and 5 women
ranging in age from 42 to 82 (median 67 ± 11.5) years.
Mean tumor size was 75.1 ± 43.4 mm (range 15 to 230
mm). HCC samples were categorized according to differ-
entiation into well (G1; seven cases), moderately (G2;
nineteen cases), or poorly (G3; seven cases) differentiated
types, which correspond to Edmondson's Grades I/II, III,
and IV [21,22]. One patient (HCC patient No. 10) had a
hepato-cholangiocellular carcinoma (Table 1). Regular
intake of more than 60 g alcohol per day over a period of
m o r e  t h a n  f i v e  y e a r s  w a s  d oc u m e n t ed  i n  t e n  p a t i e n t s.
Hereditary hemochromatosis was diagnosed in one, and
chronic hepatitis C was found in ten patients. One patient
(HCC patient No. 22) had a coinfection of HBV and HCV.
Antibodies against HBV core protein were found in two
patients (HCC patients No. 4 and No. 7) without evi-
dence of viral replication. 13 tumors were classified as
cryptogenic HCC (Table 1). Locally advanced disease was
found in five cases at the time of liver resection. Alfa feto-
protein (AFP) serum level was available from 21 patients,
ranging from 1.3 ng/ml to 95468 ng/ml (normal range <
7.0 ng/ml). In ten patients AFP level remained normal
during follow-up. Advanced liver fibrosis or liver cirrho-
sis (fibrosis stages F3 to F6) according to the Ishak's scor-
ing system [23] was confirmed in twenty-three patients
(Table 1).
Bile duct cancer (CCC)
Tissue samples were obtained from 11 patients (4 men, 7
women) with adenocarcinoma of biliary tree and gall
bladder with a mean age of 60.3 ± 8.1 years (range from
42 to 73 years) and graded as well (G1; one case), moder-
ately (G2; eight cases), or poorly (G3; two cases) differen-
tiated tumors. Two patients (CCC patients No. 9 and No.
10) developed advanced liver fibrosis (Table 2).
Benign liver tumors
Samples from seven patients (1 man, 6 women) with a
benign liver tumor, i.e. focal nodular hyperplasia (n = 6)
or liver adenoma (n = 1) were also studied (Table 2). Age
of patients ranged from 22 to 47 (mean 40 ± 6) years.
Advanced liver fibrosis was not detected in this patients'
group.
Liver metastases (M)
Tissue samples were also obtained from 34 patients (21
men, 13 women) with liver metastasis of colorectal (n =
29), gastric (n = 2), renal (n = 1), and breast (n = 2) can-
cers. Age of patients ranged from 32 to 82 (median 63.9 ±
8.2) years. Liver metastases were also categorized accord-
ing to differentiation into well (G1; two case), moderately
(G2; twenty-five cases), or poorly (G3; seven cases) differ-
entiated carcinomas (Table 3). Advanced liver fibrosis
(Ishak's stages F3 to F6) [23] was found only in one non-
cancer liver tissue (M7) (Table 3).
Tissue samples for immunohistochemistry
Only tissue slides were available for immunohistochemi-
cal analysis from further 23 patients [HCC (n = 15) (Table
1) and chronic hepatitis C (n = 8)]. All the 15 HCC
patients had a HCV-related chronic liver disease, and
four consumed also regularly alcohol. Core antibodies
against HBV were present in two patients. Liver cirrhosis
was confirmed in six samples.
The study was approved by the Ethics Committee of the
Otto-von-Guericke University of Magdeburg.
DNA extraction and sodium bisulfit modification
Genomic DNA was extracted using proteinase K diges-
tion and was modified by sodium bisulfit (CpGenome™
DNA Modification Kit, Q-Biogene Heidelberg, Germany)
as reported previously [24,25].
MethyLight assay
Genomic DNA was analyzed by MethyLight technique
after bisulfite conversion as reported previously [19,20].
Briefly, three oligonucleotids were used in every reaction.
Two locus-specific PCR primers flanked an oligonucle-
otide probe with a 5' fluorescent reported dye (6FAM)
and a 3'quencher dye (BHQ-1). Primer and probe
sequences for CDKN2A promoter (GeneBank accession
number GI 21886808) were: forward primer (bp 20012-
20033) 5'-tgg-agt-ttt-cgg-ttg-att-ggt-t-3'; reverse primer
(bp 20081-20060): 5'-aac-aac-gcc-cgc-acc-tcc-c-3'; oligo-
nucleotide probe sequence (5'-3') (bp 20060-20043):
6FAM-acc-cga-ccc-cga-acc-gcg-BHQ-1. PCR reaction
resulted in a 70-bp product including 8 CpG islandsCsepregi et al. BMC Cancer 2010, 10:317
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Table 1: Results and characteristics of patients with hepatocellular carcinoma (HCC)
Patient Etiology Non-tumor tissue Tumor tissue
Fibrosis Methylight MSP IRS Methylight
Result PMR Result PMR MSP IRS
HCC1 alcoholic 6 neg 0.08 neg 4 neg 0.14 neg 0
HCC2 cryptogenic 2 neg 0.04 neg 2 neg 3.73 pos 0
HCC3 HH 3 neg 0.01 pos 2 neg 0.04 pos 0
HCC4 alcoholic 3 neg 0.01 pos 0 neg 0.01 neg 0
HCC5 alcoholic 4 neg 1.39 neg 3 pos 100 neg 0
HCC6 cryptogenic 6 neg 0.19 pos 4 pos 14.64 pos 0
HCC7 cryptogenic 2 neg 0.01 neg 0 neg 0.41 pos 0
HCC8 alcoholic 2 neg 0.01 pos 0 pos 10.43 neg 0
HCC9 cryptogenic 5 neg 0.11 pos 4 pos 39.81 pos 0
HCC10 alcoholic* 4 neg 0.01 neg 2 pos 11.82 pos 4
HCC11 cryptogenic 2 neg 0.05 neg 2 neg 0.01 neg 3
HCC12 alcoholic 4 pos 22.44 neg 2 pos 26.86 pos 0
HCC13 alcoholic 4 neg 0.3 neg 0 pos 31.62 pos 0
HCC14 cryptogenic 1 neg 0.69 neg 3 pos 52.09 pos 0
HCC15 cryptogenic 2 neg 0.01 nd 0 pos 21.43 nd 0
HCC16 alcoholic 6 neg 0.71 pos 2 pos 100 pos 0
HCC17 cryptogenic 2 neg 0.12 nd 4 pos 22.11 nd 0
HCC18 cryptogenic 4 neg 0.15 neg 0 pos 41.06 pos 0
HCC19 alcoholic 6 neg 0.01 neg 0 pos 88.81 pos 0
HCC20 cryptogenic 2 neg 0.01 neg 2 neg 0.03 neg 0
HCC21 cryptogenic 3 neg 0.01 pos 0 pos 24.23 pos 2
HCC22 HBV/HCV 6 neg 1.46 neg 0 neg 1.92 neg 0
HCC23 HCV 1 neg 0.5 neg 0 pos 50.96 pos 0
HCC24 HCV 6 neg 0.86 neg 0 pos 7.91 pos 0
HCC25 HCV 6 neg 0.07 neg 0 neg 1.19 neg 0
HCC26 HCV 3 neg 0.19 pos 0 pos 74.13 pos 0
HCC27 HCV 6 neg 0.82 neg 0 neg 3.59 pos 0
HCC28 HCV 2 neg 2.31 neg 0 pos 11.14 pos 0
HCC29 HCV 6 neg 0.09 neg 0 pos 30.36 pos 0
HCC30 HCV 3 neg 0.19 neg 2 pos 19.78 pos 0
HCC31 HCV 5 neg 0.11 neg 0 pos 14.12 pos 4
HCC32 crpytogenic 2 neg 0.01 nd nd pos 88.22 nd nd
HCC33 cryptogenic 6 neg 0.37 neg nd pos 100 neg nd
HCC34 HCV 6 nd nd nd 0 nd nd nd 0
HCC35 HCV 6 nd nd nd 3 nd nd nd 0
HCC36 HCV/alcoholic 6 nd nd nd 0 nd nd nd 0
HCC37 HCV 5 nd nd nd 3 nd nd nd 0
HCC38 HCV 6 nd nd nd 3 nd nd nd 0
HCC39 HCV 5 nd nd nd 2 nd nd nd 0Csepregi et al. BMC Cancer 2010, 10:317
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localized on the first exon of the gene. The gene of inter-
est was then amplified and normalized to a reference set
(β-actin = ACTB) to normalize for input DNA. The spec-
ificity of reactions for methylated DNA was confirmed
using CpGenome Universal Methylated DNA [(Chemi-
con International Inc., CA, USA (subsidiary or Serologi-
cals) catalog #S7821)]. TaqMan PCR reactions were
performed in parallel with primers specific for the
bisulfite-converted methylated sequence for a particular
locus and with ACTB reference primers. The ratio
between values was calculated in these two TaqMan anal-
yses, using this approach the degree of methylation at
that locus was determined. The extent of methylation at a
specific locus was determined by the following formula:
[(gene/actb)sample: (gene/actb)SssI-treated genomic DNA]* 100.
Samples with ≥ 4% of PMR (percentage of methylated ref-
erence) were regarded as hypermethylated.
Methylation-specific PCR (MSP)
The methylation status of CDKN2A was also evaluated
by MSP as described previously[18,26]. In brief, DNA was
subjected to bisulfit modification and was amplified using
two primers specific for either methylated or unmethy-
lated sequences [18]. Primer sequences for unmethylated
reactions were sense: 5'-tta-tta-gag-ggt-ggg-gtg-gat-tgt-3'
and anti-sense: 5'-caa-ccc-caa-acc-aca-acc-ata-a-3', which
amplified a 151 bp product. Primer sequences for methy-
lated reactions were sense: 5'-tta-tta-gag-ggt-gcg-gat-cgc-
3 and anti-sense: 5'-gac-ccc-gaa-ccg-cga-ccg-taa-3',
which amplified a 150 bp product. CpGenome™ Universal
Methylated DNA (Q-Biogene, Heidelberg, Germany) was
used as positive control. DNA from normal lymphocytes
served as negative control for methylated alleles. PCR
was performed as described previously [26]. PCR prod-
ucts were run on polyacrylamide gels, followed by silver-
staining.
Immunohistochemistry
p16 expression was studied on formalin-fixed and paraf-
fin embedded tissue samples. Briefly, 3-5 μm thick tissue
sections were deparaffinized in xylol and rehydrated in a
graded alcohol series. Endogenous biotin was blocked
using the Avidin/Biotin Blocking kit (2 × 15 minutes;
Vector Laboratories, Inc., Burlingame, CA). Immunos-
taining was performed with polyclonal anti-p16 antibody
directed against the entire region of the human p16 pro-
tein (1:100; Quartett, Berlin, Germany). Incubation with
the primary antibody was performed in a moist chamber
at 37°C for 1 hour. Rabbit-anti-mouse IgG (30 minutes,
room temperature; Vector Laboratories Inc.) served as a
secondary antibody. The immunoreaction was visualized
with an streptavidin-biotin complex, using the Vectastain
ABC alkaline phosphatase kit (distributed by CAMON,
Wiesbaden, Germany). FastRed (Zytomed, Berlin, Ger-
many) served as chromogen. The specimens were coun-
ter-stained with hematoxylin. Omission of the primary
antibody served as a negative control.
Immunoreactivity Score (IRS)
For quantification of immunohistochemical results, a
numerical scoring system was applied. Only nuclear
staining was considered as positive. The observed expres-
sion of p16 in hepatocytes and tumor cells was assessed
using two categories. Category A documented the num-
ber of immunoreactive cells as 0 (no reactive cells), 1 (<
10%), 2 (11 to 50%), and 3 (> 50%). Category B docu-
mented the intensity of immunostaining as 0 (no immu-
nostaining), 1 (weak), 2 (moderate), and 3 (strong).
Finally, values for category A and B were added to con-
struct an "immunoreactivity score" (IRS) ranging from 0
to 6.
Statistical analysis
PMR (percentage of methylated reference) values of
Methylight assays were dichotomized for statistical pur-
poses as reported previously [19,20]. PMR values of
tumor and non-tumor samples were compared by Kolm-
ogorov-Smirnov test. Differences in promoter methyla-
tion rate were analysed between cancer and non-tumor
tissues using Fisher's exact test. All statistical tests were
HCC40 HCV 5 nd nd nd 6 nd nd nd 5
HCC41 HCV/alcoholic 3 nd nd nd 2 nd nd nd 0
HCC42 HCV/alcoholic 6 nd nd nd 1 nd nd nd 0
HCC43 HCV/alcoholic na nd nd nd nd nd nd nd 0
HCC44 HCV na nd nd nd nd nd nd nd 0
HCC45 HCV na nd nd nd nd nd nd nd 0
HCC46 HCV na nd nd nd nd nd nd nd 0
HCC47 HCV na nd nd nd nd nd nd nd 0
HCC48 HCV na nd nd nd nd nd nd nd 0
HCC, hepatocellular carcinoma; PMR, percentage of methylated reference (%); MSP, methylation specific PCR;
IRS = Immunoreactivity score, nd, not done; na, not available; AFP, alfa fetoprotein; * the tumor was considered as a mixed form of HCC and 
CCC; HBV, hepatitis B virus; HCV, hepatitis C virus;
Table 1: Results and characteristics of patients with hepatocellular carcinoma (HCC) (Continued)Csepregi et al. BMC Cancer 2010, 10:317
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Using Methylight assay, methylation status of 8 CpG
islands of the first exon of CDKN2A was evaluated in 33
HCCs and the corresponding non-tumor liver samples.
The mean PMR of HCC samples was 31.41 ± 27.63%
(range 0.01 to 100%) (Table 1). Twenty-three patients
with HCC (69.7%) showed a PMR > 4% and were
regarded as hypermethylated. The CDKN2A hypermeth-
ylation positive HCCs showed a mean PMR of 42.34 ±
27.8% (range 7.91 to 100%) (Table 1). A methylation of
CpG islands was detected in 4 (57%) of 7 well-differenti-
ated, 15 (79%) of 19 moderately differentiated, and 4
(57%) of 7 poorly differentiated HCCs. The frequency of
promoter hypermethylation between patients with non-
HCV induced HCC and those with HCV-induced HCC
was not different (69% vs. 70%; ns). The mean PMR of the
Table 2: Results and characteristics of patients with cholangiocellular carcinoma and benign liver tumors
Patient Liver disease/ Non-tumor tissue Tumor tissue
Primary cancer Fibrosis Methylight MSP IRS Methylight MSP IRS
score Result PMR Result PMR
Cholangiocellular carcinoma (CCC)
CCC1 bile duct 0 neg 0.01 pos 0 neg 0.01 neg 6
CCC2 bile duct 2 neg 0.01 neg 0 neg 0.04 neg 0
CCC3 bile duct 0 neg 0.01 neg 0 neg 0.01 pos 6
CCC4 bile duct 0 neg 0.01 neg 0 neg 0.8 pos 0
CCC5 gall bladder 0 neg 0.01 pos 0 pos 25.86 pos 2
CCC6 bile duct 0 neg 0.01 pos 2 neg 0.01 pos 2
CCC7 bile duct 2 neg 0.07 neg 0 neg 0.1 neg 5
CCC8 gall bladder 0 neg 0.01 neg 0 neg 3.28 neg 0
CCC9 bile duct 6 neg 0.01 neg nd neg 0.01 neg nd
CCC10 bile duct 4 neg 0.49 neg nd neg 0.27 neg nd
CCC11 gall bladder 1 neg 0.4 nd nd neg 0.01 nd nd
Benign liver tumors (B)
B1 FNH 0 neg 0.34 neg 0 neg 0.05 neg 2
B2 FNH 0 neg 0.05 neg 0 neg 0.25 neg 5
B3 hepatic adenoma 0 neg 0.01 nd 0 neg 0.01 nd 2
B4 FNH 0 neg 0.62 neg 2 neg 0.07 neg 0
B5 FNH 0 neg 0.1 nd nd neg 0.04 nd nd
B6 FNH 0 neg 0.07 nd nd neg 1.36 nd nd
B7 FNH 0 neg 0.03 nd nd neg 0.26 nd nd
PMR, percentage of methylated reference (%); MSP, methylation specific PCR, IRS = Immunoreactivity score; nd, not done; CCC, 
cholangiocellular carcinoma; FNH, focal nodular hyperplasia;Csepregi et al. BMC Cancer 2010, 10:317
http://www.biomedcentral.com/1471-2407/10/317
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Table 3: Results and characteristics of patients with liver metastasis
Patient Primary cancer Non-tumor tissue Tumor tissue
Fibrosis Methylight MSP IRS Methylight MSP IRS
score Result PMR Result PMR
Liver metastasis (M)
M1 breast 1 neg 0.05 nd 3 neg 0.02 nd 6
M2 breast 0 neg 0.04 nd 2 neg 0.01 nd 6
M3 colorectal 0 neg 0.01 nd 0 neg 0.01 nd 4
M4 colorectal 0 neg 0.01 nd 0 neg 0.01 nd 6
M5 colorectal 0 neg 0.01 nd 0 neg 0.01 nd 3
M6 colorectal 0 neg 0.01 nd 0 neg 0.01 nd 6
M7 colorectal 4 neg 0.01 nd 0 neg 0.01 nd 5
M8 colorectal 0 neg 0.01 nd 0 neg 0.01 nd 5
M9 colorectal 0 neg 0.01 nd 0 neg 0.01 nd 6
M10 colorectal 0 neg 0.01 nd 0 neg 0.01 nd 5
M11 colorectal 0 neg 0.01 nd 2 pos 39.55 nd 4
M12 colorectal 0 neg 0.01 nd 0 neg 0.01 nd 6
M13 colorectal 0 neg 0.01 neg 0 neg 0.01 neg 6
M14 colorectal 0 neg 0.02 pos 0 neg 0.01 pos 6
M15 colorectal 0 neg 0.01 neg 0 pos 52.18 neg 6
M16 colorectal 0 neg 0.09 neg 0 neg 0.74 neg 6
M17 colorectal 0 neg 0.39 neg 2 neg 0.04 neg 6
M18 colorectal 0 neg 0.73 neg 0 neg 0.12 neg 5
M19 colorectal 0 neg 0.15 neg 0 neg 0.01 neg 5
M20 colorectal 0 neg 0.17 pos 2 neg 0.01 neg 4
M21 colorectal 0 neg 0.8 neg 3 pos 57.82 pos 0
M22 colorectal 0 neg 0.54 pos 2 neg 0.35 neg 5
M23 colorectal 2 neg 0.55 pos 0 neg 0.51 neg 6
M24 colorectal 0 neg 0.38 neg 0 pos 9.88 pos 0
M25 colorectal 0 neg 0.08 pos 0 pos 6.48 neg 5
M26 gastric 0 neg 0.01 pos nd neg 0.01 neg nd
M27 gastric 0 neg 0.39 neg nd neg 0.15 neg nd
M28 colorectal 0 neg 0.09 neg nd pos 25.19 neg nd
M29 colorectal 0 neg 0.85 pos nd neg 0.07 pos nd
M30 colorectal 0 neg 0.86 neg nd neg 0.49 neg nd
M31 colorectal 0 neg 0.55 pos nd neg 1.19 pos nd
M32 renal 0 neg 0.01 nd nd neg 0.01 nd nd
M33 colorectal 1 neg 0.08 nd nd neg 0.85 nd nd
M34 colorectal 0 neg 0.03 nd nd neg 0.01 nd nd
PMR, percentage of methylated reference (%); MSP, methylation specific PCR; nd, not done;Csepregi et al. BMC Cancer 2010, 10:317
http://www.biomedcentral.com/1471-2407/10/317
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corresponding non-cancer liver tissues was 1.15 ± 1.64%
(range 0.01 to 22.41). All but one (HCC patient No. 21)
corresponding non-tumor samples obtained from
patients with HCC were found to have an unmethylated
CDKN2A promoter (Figure 1).
Next, we assessed the frequency of CDKN2A methyla-
tion in tumor and non-tumor tissue samples of 34
patients with liver metastases (Table 3) and 11 patients
with adenocarcinomas of the biliary tract and gall bladder
(CCC-group) as well as from 7 patients with benign liver
tumors (Table 2).
None of tissue samples with benign liver pathology
o b t a i n e d  f r o m  p a t i e n t s  w i t h  n o n - H C C  ( a l t o g e t h e r  5 9
samples including lesional samples of patients with
benign liver tumors) showed CpG methylation. Liver
metastases of 6 colorectal cancers (20.7%) had a mean
PMR of 39.23% (range 25.18 to 52.18%). Only one tumor
sample (9%) of the CCC-group had a PMR of 25.86%
(Tables 2 and 3) (Figure 1). PMR in liver metastases was
comparable to those results obtained from patients with
HCC.
MSP analysis
Tumor und non-tumor tissue samples from 30 patients
with HCC were studied using MSP. 30% of the non-tumor
and 70% of the tumor samples were found to be hyperm-
ethylated. There was no significant difference between
the HCV-induced tissue probes (80%) and those from
patients with HCC not related to HCV (65%) in terms of
methylation of promoter region. 17 HCC samples were
hypermethylated with both methods (MethyLight and
MSP). None of the MSP-positive non-tumor samples
showed hypermethylation analysed by MethyLight. Alto-
gether, about half of cancer probes (21 HCCs, 1 CCC, 6
liver metastases) were found hypermethylated in MSP
analysis. Among patients with MSP-positive metastatic
colorectal cancer, only 2 (patients 21 and 24) showed a
methylated promoter also in MethyLight analysis (Table
3). It was of interest that 32% of the non-neoplastic liver
tissue samples proved methylated in MSP analysis (Figure
2).
Immunohistochemical staining
148 tissue sections were obtained from 81 patients [HCC
(n = 36), CCC-group (n = 8), benign liver tumors (n = 4),
liver metastasis (n = 25) and chronic hepatitis C (n = 8)]
and were studied by immunohistochemistry for p16 pro-
tein expression. Non-cancer samples (n = 75) showed
only a weak immunoreactivity for p16 (mean IRS: 1.24) in
few hepatocytes (Figures 3 and 4). While samples (n = 45)
without significant liver fibrosis (F0 to F2) expressed no
p16 (mean IRS: 0.36), immunostaining was significantly
enhanced in samples (n = 30) with advanced liver fibrosis
or cirrhosis (F3 to F6) (mean IRS: 2.6) (p < 0.01) (Figure
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5). Here, p16 was mainly expressed by hepatocytes lining
the portal tracts and fibrous septa as well as by cells of
ductular proliferations. Nuclear p16 expression was
absent in the vast majority of HCC samples (Figure 3).
Only 5 samples (11%, mean IRS: 0.47) obtained from
moderately differentiated HCCs expressed p16 in the
nucleus. In contrast, metastatic cancer probes (23/25)
showed a strong p16 expression (mean IRS: 4.9) (p < 0.01)
(Figure 6). A complete loss of nuclear p16 expression was
seen only in two remaining samples from patients with
colorectal cancer (patients 21 and 24) (Table 3). Tissue
samples obtained from patients of the CCC-group (IRS:
2.6) or with benign liver tumors (IRS: 1.75) showed only a
moderate p16 immunostaining.
The difference of CDKN2A-methylation and p16 pro-
tein expression between HCCs and liver metastases was
statistically significant (p < 0.01, respectively). Using the
Spearman non-parametric test, no correlation between
nuclear p16 expression detected by immunohistochemi-
cal staining and CDKN2A promoter methylation using
Methylight assay could be shown.
Discussion
CDKN2A encodes a cyclin-dependent kinase inhibitor, a
negative G1-specific regulator of cell cycle and was
reported to be inactivated through extensive CpG methy-
lation in hepatitis virus-induced HCC [15]. However,
CpG islands of CDKN2A were shown to be also methy-
lated using MSP [18], a technique having limited sensitiv-
ity and specificity [19,20], in patients with chronic liver
diseases without HCC [16,17]. In order to further clarify
this issue, in the first step of our analysis, we focused on
epigenetic changes of CDKN2A evaluating the methyla-
tion status of CpG islands on the first exon. MethyLight
provides a sensitive tool for detecting CpG methylation
[19,20] and also allows to quantitatively assess the grade
of methylation. Our findings indicate that methylation of
CpG islands at the 5'end of the first exon of CDKN2A
detected by MethyLight, but not by MSP, may serve as a
specific marker of HCC since it was frequently found in
HCCs and detected only in one non-cancer sample. Epi-
genetic changes of CpG islands are probably related not
only to chronic viral hepatitis as suggested in several pre-
vious reports [16,17,27]. In our study patients with non-
HCV induced HCC showed the same frequency of pro-
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moter hypermethylation as HCV induced HCCs. Hyper-
methylation of CDKN2A gene was not found in any of
the extralesional liver tissue samples obtained from
patients with chronic hepatitis C. 20% of patients with
liver metastases of colorectal cancers had methylated
CpG islands and that frequency is somewhat lower than
reported in the literature [25,28,29].
In previous studies it was shown that p16 was
expressed at very low levels in mammalian tissues sug-
gesting that this protein may have no impact on the nor-
mal development of cells [30,31]. In our study, non-
cancer liver samples without advanced fibrosis failed to
express p16 in the nucleus suggesting that p16 is
expressed only at low levels in non-neoplastic tissue. In
contrast, in patients with severe liver fibrosis or cirrhosis
which are considered as a preneoplastic condition for
HCC, an increased nuclear p16 expression was observed.
Nuclear p16 expression was not detected in the majority
of HCCs indicating that loss of p16 may be a common
event during hepatocarcinogensis [15]. The absence of
p16 expression resulting from either methylation or
m u t a t i o n  o f  C D K N 2 A  g e n e  m a y  p r o b a b l y  r e f l e c t
Figure 3 Quantitative differences of p16 protein expression. In liver tumors and non-neoplastic tissue samples the quantitative differences of p16 
expression evaluated by immunohistochemical detection of p16 using an immunoreactivity score (IRS) are shown.
Figure 4 Immunohistochemical expression of p16 in non-neoplastic liver tissue and hepatocellular carcinoma. A moderately differentiated 
HCC is completely immunonegative for p16 (left). The non-neoplastic liver tissue shows immunostaining for p16 in scattered ductular reactions and 
mild cytoplasmic immunostaining in few periportal and periseptal hepatocytes (right). Anti-p16-antibody. Hematoxylin-counterstain.
1598/99/02 1598/99/02Csepregi et al. BMC Cancer 2010, 10:317
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increased selection pressure at this neoplastic stage for
loss of p16 expression. In our study, we found no correla-
tion between methylation of the first exon of CDKN2A
gene and nuclear expression of p16.
Data on p16 protein expression in liver metastases are
scarce. Dai et al reported [32] that 89% of colon ade-
nomas, 65% of colon carcinomas and 100% of liver metas-
tasis of colon cancer expressed p16. In line with these
results, liver metastases from colon cancers showed also
in our study a strong p16 expression. Overexpression of
p16 in metastatic tissue samples appeared to be paradoxi-
cal and was seen in several primary gastrointestinal
tumors [32-34]. The precise reason why negative regula-
Figure 5 Immunohistochemical expression of p16 in non-tumor liver sample. The non-neoplastic liver tissue shows strong immunostaining for 









































Figure 6 Immunohistochemical detection of p16 in a liver metastasis. Liver metastasis of a moderately differentiated colorectal cancer with 
strong cytoplasmic and also nuclear expression of p16 in tumor cells. Non-neoplastic liver tissue adjacent to colorectal cancer metastasis is completely 
devoid of p16 expression. Anti-p16-antibody. Hematoxylin-counterstain.Csepregi et al. BMC Cancer 2010, 10:317
http://www.biomedcentral.com/1471-2407/10/317
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tors of the cell cycle often display increased expression is
unknown at present and remains to be elucidated.
Conclusions
In summary, using MethyLight assay for epigenetic stud-
ies of CDKN2A in patients with liver tumors we showed
that CDKN2A methylation is a putative marker of HCC.
MSP compared to MethyLight seems to be unspecific in
patients with liver tumors.
Our data also indicate that the combined analysis of
CDKN2A methylation and immunohistochemical stain-
ing for p16 expression might be an approach to distin-
guish HCC from non-HCC liver tumors and liver
metastases. Moreover, it is of particular interest that p16
expression seems to correlate with the grade of liver
fibrosis. This finding deserves further studies.
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